Metastatic Renal Cell Carcinoma

In 2024, the treatment landscape for kidney cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.

Combining gut microbiome manipulation with immunotherapy and tyrosine kinase inhibitor therapy conveyed clinical benefit for patients with metastatic renal cell carcinoma, results of a randomized phase 1 trial showed.

Steven A. Rosenberg, MD, PhD, FAACR, will be awarded the 2024 American Association for Cancer Research Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting in San Diego.

NASHVILLE, Tenn. — Insurance status appeared associated with survival among patients with metastatic renal cell carcinoma, according to findings presented at International Kidney Cancer Symposium: North America.

Practice type may significantly influence providers’ choice of first-line therapy for metastatic renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Cytoreductive nephrectomy may extend OS for a well-selected population of patients with metastatic renal cell carcinoma, according to study results published in Cancer.

Targeted therapies appeared associated with modest improvements in OS compared with nontargeted therapies among elderly patients with metastatic renal cell carcinoma, according to results of a retrospective study published in JAMA Network Open.

Immune therapy combinations have made a tremendous impact on life expectancy and induced long-term remissions. Targeted therapy has also made big strides in improving outcomes. Cancer genomics has the potential to help us customize therapy in the future.

In 2017, the positive results of two trials — CheckMate-214 and CABOSUN — garnered a great deal of attention and discussion, and prompted many in the field to claim that a revolution is underway in the management of patients with metastatic renal cell carcinoma. To better understand the implications of these trials, Healio spoke with Neeraj Agarwal, MD, director of the genitourinary oncology program and associate professor of medicine at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, who discussed the key findings, and shared his thoughts on how the landscape of metastatic renal cell carcinoma therapies may change in the coming years.

The 21st century has witnessed several practice-changing advances in managing patients with renal cell carcinoma, including a steadily growing armamentarium that has resulted in improved patient outlook. In an interview with Healio, Brian I. Rini, MD, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and staff member at the Cleveland Clinic’s Taussig Cancer Institute, shared his thoughts on these changes and what drives him in research, and offered a glimpse at what he believes the future of renal cell carcinoma treatment will entail.